Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 11/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15124799 | 1.00 | MEN1 (0.50) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL8353739 | 1.00 | MEN1 (0.50) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL15124794 | 1.00 | MEN1 (0.50) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL22473734 | 1.00 | MEN1 (0.50) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL3439703 | 1.00 | MEN1 (0.50) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL21372526 | 0.96 | MEN1 (0.46) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL16504745 | 0.96 | MEN1 (0.46) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL16504878 | 0.96 | MEN1 (0.46) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL15537106 | 0.96 | MEN1 (0.46) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL20122287 | 0.96 | MEN1 (0.46) | MEN1GAAKMT2ACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613600-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-7241775-B2 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1613600-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050009863-A1 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004085404-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | WO | disclosed |
| EP-0966464-B1 | SUBSTITUTED 2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6114330-A | BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0966464-A1 | SUBSTITUTED 2,4-DIAMINOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998039328-A1 | SUBSTITUTED 2,4-DIAMINOPYRIMIDINES | F.HOFFMANN-LA ROCHE AG (CH) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009863-A1 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | CYP27A1, CYP11B2, CYP7A1 | MEN1 3067/4885GAA 1155/4885KMT2A 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.